| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.688 | 0.002 | 0.688 | NMDA 2B receptor antagonist | 0.065 0.028 DBMET00327 | ||
| 0.689 | 0.004 | 0.689 | Glutamate receptor antagonist | 0.472 0.005 DBMET00327 | ||
| 0.641 | 0.02 | 0.641 | Analgesic | |||
| 0.62 | 0.004 | 0.62 | NMDA receptor antagonist | 0.412 0.004 DBMET00327 | ||
| 0.575 | 0.015 | 0.575 | 5 Hydroxytryptamine release inhibitor | 0.488 0.036 DBMET00327 | ||
| 0.473 | 0.004 | 0.473 | NMDA 2 receptor antagonist | |||
| 0.481 | 0.031 | 0.481 | GABA C receptor rho-3 antagonist | 0.462 0.037 DBMET00327 | ||
| 0.406 | 0.004 | 0.406 | ATPase inhibitor | 0.172 0.068 DBMET00327 | ||
| 0.402 | 0.009 | 0.402 | Amylase inhibitor | 0.225 0.036 DBMET00327 | ||
| 0.381 | 0.004 | 0.381 | Autotaxin inhibitor | |||
| 0.471 | 0.1 | 0.471 | Antiinflammatory | |||
| 0.368 | 0.004 | 0.368 | Dopamine D2 agonist | |||
| 0.42 | 0.065 | 0.42 | Histamine release inhibitor | 0.394 0.079 DBMET00327 | ||
| 0.396 | 0.048 | 0.424 | Aldehyde oxidase inhibitor | 0.424 0.044 DBMET00327 | DBMET00327 | |
| 0.377 | 0.043 | 0.417 | Lipoxygenase inhibitor | 0.417 0.033 DBMET00327 | DBMET00327 | |
| 0.327 | 0.009 | 0.336 | Alkaline phosphatase inhibitor | 0.336 0.008 DBMET00327 | DBMET00327 | |
| 0.32 | 0.004 | 0.32 | NMDA 2C receptor antagonist | 0.061 0.043 DBMET00327 | ||
| 0.324 | 0.027 | 0.324 | RNA-directed DNA polymerase inhibitor | 0.254 0.047 DBMET00327 | ||
| 0.304 | 0.017 | 0.304 | Cyclooxygenase inhibitor | 0.273 0.022 DBMET00327 | ||
| 0.36 | 0.081 | 0.36 | Calpain 2 inhibitor | |||
| 0.284 | 0.007 | 0.284 | Nav1.6 sodium channel blocker | |||
| 0.271 | 0.004 | 0.271 | Mineralocorticoid receptor antagonist | |||
| 0.283 | 0.025 | 0.283 | Diuretic | |||
| 0.295 | 0.042 | 0.295 | Anticonvulsant | |||
| 0.255 | 0.002 | 0.283 | Kynurenine 3 monooxygenase inhibitor | 0.283 0.002 DBMET00327 | DBMET00327 | |
| 0.297 | 0.046 | 0.314 | 5 Hydroxytryptamine uptake stimulant | 0.314 0.038 DBMET00327 | DBMET00327 | |
| 0.258 | 0.007 | 0.258 | HIV-1 reverse transcriptase inhibitor | |||
| 0.257 | 0.013 | 0.257 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.262 | 0.02 | 0.262 | Hemostatic | |||
| 0.246 | 0.005 | 0.246 | Macrophage migration inhibitory factor inhibitor | 0.229 0.006 DBMET00327 | ||
| 0.306 | 0.068 | 0.306 | 5 Hydroxytryptamine release stimulant | |||
| 0.239 | 0.007 | 0.239 | Dopamine agonist | |||
| 0.272 | 0.044 | 0.272 | Ca2+/calmodulin-dependent kinase II beta inhibitor | |||
| 0.249 | 0.025 | 0.249 | Antipruritic | |||
| 0.241 | 0.021 | 0.241 | Insulin secretagoues | |||
| 0.292 | 0.073 | 0.292 | Spasmolytic | |||
| 0.224 | 0.01 | 0.224 | Potassium channel (Ca-activated) activator | 0.079 0.077 DBMET00327 | ||
| 0.214 | 0.007 | 0.214 | Inducible nitric-oxide synthase inhibitor | 0.154 0.015 DBMET00327 | ||
| 0.249 | 0.045 | 0.249 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | |||
| 0.204 | 0.006 | 0.204 | Potassium channel large-conductance Ca-activated activator | |||
| 0.314 | 0.125 | 0.314 | Antibacterial | 0.232 0.194 DBMET00327 | ||
| 0.222 | 0.034 | 0.254 | Succinate dehydrogenase inhibitor | 0.254 0.021 DBMET00327 | DBMET00327 | |
| 0.259 | 0.076 | 0.259 | Cardiotonic | |||
| 0.234 | 0.053 | 0.234 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | |||
| 0.182 | 0.005 | 0.352 | NMDA receptor subunit 3B antagonist | 0.352 0.003 DBMET00327 | DBMET00327 | |
| 0.226 | 0.054 | 0.226 | Neurotrophic factor enhancer | 0.196 0.08 DBMET00327 | ||
| 0.278 | 0.107 | 0.278 | Vasodilator, coronary | |||
| 0.211 | 0.046 | 0.211 | 3C-like protease (Human coronavirus) inhibitor | |||
| 0.175 | 0.012 | 0.175 | Electrolyte absorption antagonist | 0.132 0.028 DBMET00327 | ||
| 0.169 | 0.016 | 0.169 | Nitric-oxide synthase inhibitor | 0.144 0.025 DBMET00327 | ||
| 0.168 | 0.016 | 0.168 | Phosphodiesterase 7B inhibitor | |||
| 0.326 | 0.179 | 0.326 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.149 | 0.005 | 0.149 | 5 Hydroxytryptamine 2A agonist | |||
| 0.228 | 0.085 | 0.228 | DNA synthesis inhibitor | 0.227 0.086 DBMET00327 | ||
| 0.157 | 0.016 | 0.157 | Acetylcholine M3 receptor agonist | |||
| 0.179 | 0.038 | 0.179 | Sodium channel (voltage-gated) blocker | |||
| 0.148 | 0.007 | 0.148 | NMDA 2A receptor antagonist | |||
| 0.211 | 0.072 | 0.225 | Nitric-oxide synthase stimulant | 0.225 0.054 DBMET00327 | DBMET00327 | |
| 0.144 | 0.007 | 0.144 | Kallikrein 1 inhibitor | |||
| 0.162 | 0.03 | 0.162 | GABA receptor agonist | |||
| 0.25 | 0.118 | 0.25 | Thyroid hormone beta antagonist | |||
| 0.132 | 0.004 | 0.132 | Factor XIa inhibitor | |||
| 0.161 | 0.034 | 0.161 | Alpha 2b adrenoreceptor antagonist | 0.156 0.036 DBMET00327 | ||
| 0.143 | 0.017 | 0.143 | MAP-kinase-activated kinase inhibitor | |||
| 0.248 | 0.125 | 0.248 | Thyroid hormone antagonist | |||
| 0.136 | 0.015 | 0.136 | MAP-kinase-activated kinase 2 inhibitor | |||
| 0.148 | 0.027 | 0.148 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.083 0.075 DBMET00327 | ||
| 0.169 | 0.052 | 0.169 | GABA C receptor rho-2 antagonist | 0.152 0.072 DBMET00327 | ||
| 0.143 | 0.026 | 0.143 | DNA directed RNA polymerase inhibitor | |||
| 0.123 | 0.006 | 0.251 | NMDA receptor subunit 3A antagonist | 0.251 0.004 DBMET00327 | DBMET00327 | |
| 0.22 | 0.104 | 0.224 | Tyrosine 3 hydroxylase inhibitor | 0.224 0.097 DBMET00327 | DBMET00327 | |
| 0.124 | 0.009 | 0.124 | Acetylcholine M5 receptor agonist | |||
| 0.131 | 0.017 | 0.131 | Bromodomain-containing protein 2 inhibitor | |||
| 0.122 | 0.008 | 0.122 | NMDA receptor glycine site agonist | |||
| 0.255 | 0.141 | 0.255 | Calcium channel activator | |||
| 0.122 | 0.01 | 0.122 | Alpha 2 adrenoreceptor agonist | |||
| 0.118 | 0.007 | 0.118 | Phospholipase D inhibitor | |||
| 0.132 | 0.025 | 0.132 | 5 Hydroxytryptamine agonist | |||
| 0.129 | 0.022 | 0.129 | Protein kinase B gamma inhibitor | |||
| 0.144 | 0.039 | 0.144 | 5 Hydroxytryptamine 3A agonist | |||
| 0.128 | 0.025 | 0.167 | NADH dehydrogenase inhibitor | 0.167 0.014 DBMET00327 | DBMET00327 | |
| 0.167 | 0.069 | 0.193 | Arachidonic acid antagonist | 0.193 0.04 DBMET00327 | DBMET00327 | |
| 0.111 | 0.016 | 0.111 | NMDA receptor agonist | |||
| 0.21 | 0.119 | 0.21 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.095 | 0.004 | 0.095 | Factor XI inhibitor | |||
| 0.132 | 0.042 | 0.132 | GABA C receptor agonist | 0.118 0.051 DBMET00327 | ||
| 0.12 | 0.032 | 0.12 | Potassium channel activator | |||
| 0.102 | 0.015 | 0.102 | GABA receptor antagonist | |||
| 0.096 | 0.01 | 0.096 | 5 Hydroxytryptamine 2 agonist | |||
| 0.118 | 0.032 | 0.135 | Dopamine antagonist | 0.135 0.029 DBMET00327 | DBMET00327 | |
| 0.168 | 0.082 | 0.168 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | |||
| 0.191 | 0.107 | 0.191 | Aryl hydrocarbon receptor agonist | |||
| 0.089 | 0.005 | 0.089 | Fructose-1,6-bisphosphatase inhibitor | 0.088 0.005 DBMET00327 | ||
| 0.12 | 0.037 | 0.12 | Acetylcholine agonist | |||
| 0.148 | 0.066 | 0.148 | Adenylate cyclase stimulant | 0.141 0.079 DBMET00327 | ||
| 0.103 | 0.021 | 0.326 | Phosphodiesterase III inhibitor | 0.326 0.004 DBMET00327 | DBMET00327 | |
| 0.105 | 0.024 | 0.12 | D-Ala-D-Ala ligase inhibitor | 0.12 0.014 DBMET00327 | DBMET00327 | |
| 0.093 | 0.013 | 0.391 | Phosphodiesterase 3B inhibitor | 0.391 0.003 DBMET00327 | DBMET00327 | |
| 0.143 | 0.064 | 0.145 | Ca2+-transporting ATPase inhibitor | 0.145 0.055 DBMET00327 | DBMET00327 | |
| 0.104 | 0.026 | 0.104 | Alpha adrenoreceptor agonist | |||
| 0.081 | 0.003 | 0.081 | Elastase 2A inhibitor | |||
| 0.081 | 0.003 | 0.081 | Elastase 2 inhibitor | |||
| 0.094 | 0.016 | 0.094 | 5 Hydroxytryptamine 1A agonist | |||
| 0.141 | 0.064 | 0.141 | Sodium channel blocker | |||
| 0.085 | 0.01 | 0.085 | Progesterone antagonist | |||
| 0.112 | 0.038 | 0.112 | Androgen antagonist | |||
| 0.105 | 0.031 | 0.112 | Dopamine D2 antagonist | 0.112 0.029 DBMET00327 | DBMET00327 | |
| 0.142 | 0.07 | 0.142 | Pregnane X receptor agonist | |||
| 0.093 | 0.022 | 0.093 | 5 Hydroxytryptamine 1 agonist | |||
| 0.096 | 0.025 | 0.096 | Nav1.7 sodium channel blocker | |||
| 0.283 | 0.213 | 0.283 | Caspase 9 stimulant | 0.282 0.214 DBMET00327 | ||
| 0.17 | 0.1 | 0.17 | Psychostimulant | |||
| 0.079 | 0.008 | 0.079 | Factor VII inhibitor | |||
| 0.125 | 0.056 | 0.125 | 5 Hydroxytryptamine 2B antagonist | 0.102 0.081 DBMET00327 | ||
| 0.101 | 0.032 | 0.101 | 5 Hydroxytryptamine 1A antagonist | |||
| 0.073 | 0.004 | 0.073 | ATP citrate lysase inhibitor | 0.068 0.004 DBMET00327 | ||
| 0.111 | 0.044 | 0.111 | MAP kinase kinase 1 inhibitor | |||
| 0.071 | 0.005 | 0.071 | Endothelial nitric-oxide synthase inhibitor | |||
| 0.122 | 0.057 | 0.281 | Cystathionine beta-synthase inhibitor | 0.281 0.011 DBMET00327 | DBMET00327 | |
| 0.095 | 0.031 | 0.095 | CDC25A inhibitor | |||
| 0.113 | 0.05 | 0.113 | Alpha adrenoreceptor antagonist | |||
| 0.068 | 0.004 | 0.068 | Calcitonin gene-related peptide antagonist | |||
| 0.084 | 0.02 | 0.084 | GABA A receptor antagonist | |||
| 0.073 | 0.01 | 0.073 | Potassium channel (Inward rectifier) activator | |||
| 0.079 | 0.017 | 0.079 | AMPA receptor antagonist | |||
| 0.077 | 0.016 | 0.077 | Kallikrein inhibitor | |||
| 0.074 | 0.013 | 0.074 | Aldosterone antagonist | |||
| 0.081 | 0.02 | 0.081 | Thromboxane antagonist | |||
| 0.077 | 0.016 | 0.077 | Thromboxane A2 antagonist | |||
| 0.07 | 0.01 | 0.07 | Potassium channel (ATP-sensitive) activator | |||
| 0.128 | 0.07 | 0.133 | Alpha-N-acetylglucosaminidase inhibitor | 0.133 0.066 DBMET00327 | DBMET00327 | |
| 0.095 | 0.037 | 0.095 | Glycine receptor antagonist | |||
| 0.115 | 0.057 | 0.115 | Ferrochelatase inhibitor | |||
| 0.078 | 0.021 | 0.078 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.077 0.021 DBMET00327 | ||
| 0.101 | 0.047 | 0.101 | Alpha 2 adrenoreceptor antagonist | 0.076 0.071 DBMET00327 | ||
| 0.077 | 0.024 | 0.077 | MDM2 inhibitor | |||
| 0.175 | 0.124 | 0.175 | ErbB-1 antagonist | |||
| 0.117 | 0.066 | 0.117 | 5 Hydroxytryptamine antagonist | |||
| 0.106 | 0.055 | 0.138 | UDP-glucose 4-epimerase inhibitor | 0.138 0.034 DBMET00327 | DBMET00327 | |
| 0.078 | 0.028 | 0.078 | Aryl hydrocarbon receptor antagonist | |||
| 0.09 | 0.041 | 0.09 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.055 | 0.006 | 0.055 | Carnitine palmitoyltransferase 1 inhibitor | |||
| 0.055 | 0.006 | 0.055 | Carnitine palmitoyltransferase inhibitor | |||
| 0.182 | 0.133 | 0.182 | Calpain inhibitor | |||
| 0.092 | 0.043 | 0.092 | Glutamate receptor agonist | |||
| 0.138 | 0.091 | 0.138 | Anticoagulant | |||
| 0.061 | 0.014 | 0.061 | Purinergic P2X4 antagonist | |||
| 0.091 | 0.045 | 0.091 | Acetylcholine nicotinic agonist | |||
| 0.163 | 0.117 | 0.163 | HERG channel blocker | |||
| 0.06 | 0.014 | 0.06 | Dopamine D3 agonist | |||
| 0.124 | 0.078 | 0.133 | NADPH oxidase inhibitor | 0.133 0.068 DBMET00327 | DBMET00327 | |
| 0.094 | 0.049 | 0.094 | Interleukin 5 antagonist | 0.09 0.055 DBMET00327 | ||
| 0.107 | 0.062 | 0.128 | DOPA decarboxylase inhibitor | 0.128 0.036 DBMET00327 | DBMET00327 | |
| 0.065 | 0.02 | 0.065 | Acetylcholine M1 receptor agonist | |||
| 0.12 | 0.075 | 0.12 | Cathepsin H inhibitor | |||
| 0.069 | 0.024 | 0.069 | Prostaglandin E2 antagonist | |||
| 0.071 | 0.027 | 0.071 | Acetylcholine muscarinic agonist | |||
| 0.061 | 0.017 | 0.061 | Adenylate cyclase 1 inhibitor | |||
| 0.082 | 0.038 | 0.082 | GABA B receptor agonist | 0.07 0.068 DBMET00327 | ||
| 0.077 | 0.035 | 0.259 | Dopamine D1 antagonist | 0.259 0.007 DBMET00327 | DBMET00327 | |
| 0.074 | 0.032 | 0.074 | Glutamate (mGluR6) antagonist | |||
| 0.089 | 0.049 | 0.089 | GABA A receptor agonist | |||
| 0.067 | 0.027 | 0.067 | Neuropeptide Y5 antagonist | |||
| 0.098 | 0.058 | 0.098 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.149 | 0.109 | 0.149 | Phospholipase C inhibitor | 0.14 0.127 DBMET00327 | ||
| 0.08 | 0.041 | 0.08 | Vanilloid 4 agonist | |||
| 0.092 | 0.054 | 0.092 | Ca(v)2.2 blocker | |||
| 0.054 | 0.016 | 0.054 | GABA B receptor antagonist | 0.047 0.023 DBMET00327 | ||
| 0.066 | 0.028 | 0.066 | CC chemokine 2 receptor antagonist | |||
| 0.042 | 0.004 | 0.042 | Acid ceramidase inhibitor | |||
| 0.071 | 0.034 | 0.071 | 5 Hydroxytryptamine 3 agonist | 0.06 0.049 DBMET00327 | ||
| 0.129 | 0.092 | 0.494 | Peroxidase inhibitor | 0.494 0.01 DBMET00327 | DBMET00327 | |
| 0.039 | 0.005 | 0.039 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.022 0.02 DBMET00327 | ||
| 0.124 | 0.09 | 0.124 | Lipid peroxidase inhibitor | |||
| 0.075 | 0.042 | 0.075 | Peroxisome proliferator-activated receptor gamma antagonist | 0.074 0.044 DBMET00327 | ||
| 0.071 | 0.038 | 0.071 | 5 Hydroxytryptamine uptake inhibitor | |||
| 0.107 | 0.073 | 0.107 | Nav1.5 sodium channel blocker | |||
| 0.046 | 0.013 | 0.046 | Acetylcholine M4 receptor agonist | |||
| 0.066 | 0.035 | 0.066 | Plasminogen activator inhibitor | |||
| 0.084 | 0.053 | 0.084 | Adrenaline agonist | |||
| 0.063 | 0.033 | 0.063 | Nicotinic neuronal receptor agonist | |||
| 0.064 | 0.034 | 0.064 | Beta 2 adrenoreceptor agonist | |||
| 0.107 | 0.077 | 0.11 | TRPA1 agonist | 0.11 0.071 DBMET00327 | DBMET00327 | |
| 0.049 | 0.02 | 0.049 | Factor VIIa inhibitor | |||
| 0.096 | 0.067 | 0.096 | Glutamate (mGluR7) agonist | |||
| 0.052 | 0.023 | 0.052 | Benzodiazepine antagonist | |||
| 0.042 | 0.014 | 0.042 | Potassium channel small-conductance Ca-activated activator | |||
| 0.094 | 0.066 | 0.106 | Sphingomyelinase inhibitor | 0.106 0.053 DBMET00327 | DBMET00327 | |
| 0.121 | 0.095 | 0.121 | Sphingosine 1-phosphate receptor 2 antagonist | 0.116 0.106 DBMET00327 | ||
| 0.127 | 0.102 | 0.127 | Thiol protease inhibitor | |||
| 0.053 | 0.028 | 0.053 | Glutamate (mGluR group I) agonist | |||
| 0.047 | 0.022 | 0.047 | Alpha 1L adrenoreceptor agonist | |||
| 0.06 | 0.036 | 0.06 | Alpha 1 adrenoreceptor agonist | |||
| 0.2 | 0.177 | 0.2 | Antithrombotic | |||
| 0.037 | 0.015 | 0.037 | Cholesterol ester transfer protein antagonist | |||
| 0.071 | 0.05 | 0.071 | Benzodiazepine agonist | |||
| 0.112 | 0.091 | 0.112 | Glycogen synthase kinase-3 alpha inhibitor | |||
| 0.028 | 0.008 | 0.028 | Imidazoline I1 receptor antagonist | |||
| 0.05 | 0.029 | 0.05 | Glutamate (mGluR5) antagonist | |||
| 0.088 | 0.067 | 0.088 | Glutamate release inhibitor | 0.088 0.066 DBMET00327 | ||
| 0.093 | 0.073 | 0.093 | GABA C receptor rho-1 antagonist | |||
| 0.072 | 0.052 | 0.113 | Lipase inhibitor | 0.113 0.021 DBMET00327 | DBMET00327 | |
| 0.151 | 0.132 | 0.151 | Insulin sensitizer | |||
| 0.061 | 0.042 | 0.073 | Purinergic P2X1 antagonist | 0.073 0.029 DBMET00327 | DBMET00327 | |
| 0.099 | 0.08 | 0.106 | GABA C receptor antagonist | 0.106 0.07 DBMET00327 | DBMET00327 | |
| 0.069 | 0.05 | 0.069 | Prostaglandin-E synthase inhibitor | |||
| 0.082 | 0.064 | 0.082 | Histamine N-methyltransferase inhibitor | |||
| 0.033 | 0.014 | 0.033 | Carnitine palmitoyltransferase 1A inhibitor | |||
| 0.038 | 0.02 | 0.038 | Plasma kallikrein inhibitor | |||
| 0.054 | 0.037 | 0.054 | Nicotinic alpha7 receptor agonist | |||
| 0.06 | 0.043 | 0.07 | Carbamoyl phosphate synthetase inhibitor | 0.07 0.035 DBMET00327 | DBMET00327 | |
| 0.047 | 0.03 | 0.047 | Glutamate (mGluR5) agonist | |||
| 0.089 | 0.073 | 0.151 | Creatine kinase inhibitor | 0.151 0.024 DBMET00327 | DBMET00327 | |
| 0.094 | 0.077 | 0.094 | Mediator release inhibitor | |||
| 0.098 | 0.081 | 0.098 | Protein kinase C gamma inhibitor | |||
| 0.034 | 0.018 | 0.034 | Prostaglandin EP3 antagonist | |||
| 0.069 | 0.054 | 0.069 | Epoxide hydrolase inhibitor | |||
| 0.049 | 0.034 | 0.049 | Bromodomain-containing protein 3 inhibitor | |||
| 0.058 | 0.043 | 0.058 | Androgen agonist | 0.054 0.05 DBMET00327 | ||
| 0.071 | 0.056 | 0.088 | Alpha 2a adrenoreceptor antagonist | 0.088 0.043 DBMET00327 | DBMET00327 | |
| 0.056 | 0.042 | 0.056 | Dopamine uptake inhibitor | |||
| 0.102 | 0.088 | 0.102 | Microtubule formation inhibitor | |||
| 0.109 | 0.096 | 0.109 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.055 | 0.042 | 0.055 | 5 Hydroxytryptamine 7 agonist | |||
| 0.107 | 0.094 | 0.107 | Cyclooxygenase 3 inhibitor | |||
| 0.055 | 0.043 | 0.064 | Pregnane X receptor antagonist | 0.064 0.023 DBMET00327 | DBMET00327 | |
| 0.041 | 0.029 | 0.057 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.057 0.009 DBMET00327 | DBMET00327 | |
| 0.066 | 0.054 | 0.066 | Glutamate (mGluR group I) antagonist | |||
| 0.019 | 0.009 | 0.019 | Calcitonin gene-related peptide 1 receptor antagonist | |||
| 0.039 | 0.029 | 0.047 | CF transmembrane conductance regulator antagonist | 0.047 0.011 DBMET00327 | DBMET00327 | |
| 0.02 | 0.011 | 0.02 | Progesterone agonist | |||
| 0.038 | 0.03 | 0.038 | Dopamine D5 agonist | 0.038 0.031 DBMET00327 | ||
| 0.134 | 0.126 | 0.134 | Platelet adhesion inhibitor | |||
| 0.065 | 0.057 | 0.065 | Exportin-1 inhibitor | |||
| 0.089 | 0.081 | 0.089 | 5 Hydroxytryptamine 2 antagonist | |||
| 0.045 | 0.038 | 0.045 | Carnitine palmitoyltransferase 1B inhibitor | |||
| 0.036 | 0.029 | 0.036 | TRPM8 blocker | |||
| 0.082 | 0.075 | 0.082 | HIV-1 integrase (Overall Integration) inhibitor | 0.082 0.075 DBMET00327 | ||
| 0.042 | 0.035 | 0.042 | Histamine H1 receptor agonist | |||
| 0.05 | 0.043 | 0.05 | Acetylcholine M2 receptor agonist | |||
| 0.081 | 0.074 | 0.084 | Triose-phosphate isomerase inhibitor | 0.084 0.069 DBMET00327 | DBMET00327 | |
| 0.025 | 0.019 | 0.025 | Sodium/glucose cotransporter inhibitor | |||
| 0.026 | 0.02 | 0.026 | Integrin alpha2beta1 antagonist | |||
| 0.052 | 0.046 | 0.052 | Dihydroorotate oxidase inhibitor | |||
| 0.061 | 0.057 | 0.061 | Alpha 1a adrenoreceptor antagonist | |||
| 0.014 | 0.01 | 0.014 | Glucagon agonist | |||
| 0.051 | 0.048 | 0.119 | Dopamine D4 antagonist | 0.119 0.022 DBMET00327 | DBMET00327 | |
| 0.034 | 0.031 | 0.034 | Integrin alpha2 antagonist | |||
| 0.035 | 0.033 | 0.035 | Vascular adhesion protein 1 inhibitor | |||
| 0.065 | 0.063 | 0.065 | Alpha 1 adrenoreceptor antagonist | |||
| 0.144 | 0.142 | 0.144 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.068 | 0.066 | 0.068 | GABA aminotransferase inhibitor | |||
| 0.064 | 0.063 | 0.064 | Vanilloid antagonist | |||
| 0.1 | 0.118 | 0.188 | Interleukin 4 antagonist | 0.188 0.026 DBMET00327 | DBMET00327 | |
| 0.038 | 0.057 | 0.045 | Glucose-6-phosphate isomerase inhibitor | 0.045 0.038 DBMET00327 | DBMET00327 | |
| 0.024 | 0.044 | 0.048 | Phosphoglycerate kinase inhibitor | 0.048 0.015 DBMET00327 | DBMET00327 | |
| 0.043 | 0.066 | 0.068 | Dopamine D3 antagonist | 0.068 0.039 DBMET00327 | DBMET00327 | |
| 0.106 | 0.129 | 0.158 | Mannose-6-phosphate isomerase inhibitor | 0.158 0.058 DBMET00327 | DBMET00327 | |
| 0.027 | 0.05 | 0.055 | Urate transporter 1 inhibitor | 0.055 0.016 DBMET00327 | DBMET00327 | |
| 0.064 | 0.088 | 0.122 | Chymotrypsin inhibitor | 0.122 0.025 DBMET00327 | DBMET00327 | |
| 0.064 | 0.088 | 0.103 | Estrogen receptor alpha antagonist | 0.103 0.025 DBMET00327 | DBMET00327 | |
| 0.117 | 0.142 | 0.145 | Interferon gamma antagonist | 0.145 0.085 DBMET00327 | DBMET00327 | |
| 0.048 | 0.083 | 0.094 | Histidine decarboxylase inhibitor | 0.094 0.034 DBMET00327 | DBMET00327 | |
| 0.151 | 0.186 | 0.167 | Superoxide dismutase inhibitor | 0.167 0.159 DBMET00327 | DBMET00327 | |
| 0.067 | 0.106 | 0.097 | Urease inhibitor | 0.097 0.071 DBMET00327 | DBMET00327 | |
| 0.018 | 0.062 | 0.035 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.035 0.019 DBMET00327 | DBMET00327 | |
| 0.112 | 0.156 | 0.344 | Amyloid beta precursor protein antagonist | 0.344 0.01 DBMET00327 | DBMET00327 | |
| 0.036 | 0.095 | 0.057 | Protease activated receptor antagonist | 0.057 0.051 DBMET00327 | DBMET00327 | |
| 0.037 | 0.097 | 0.055 | Fatty acid synthase inhibitor | 0.055 0.042 DBMET00327 | DBMET00327 | |
| 0.104 | 0.196 | 0.407 | P-glycoprotein inhibitor | 0.407 0.015 DBMET00327 | DBMET00327 | |
| 0.162 | 0.256 | 0.21 | 15-Lipoxygenase inhibitor | 0.21 0.202 DBMET00327 | DBMET00327 | |
| 0.127 | 0.221 | 0.157 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.157 0.134 DBMET00327 | DBMET00327 | |
| 0.063 | 0.17 | 0.277 | Cyclooxygenase 1 inhibitor | 0.277 0.017 DBMET00327 | DBMET00327 | |
| 0.132 | 0.239 | 0.201 | 12-Lipoxygenase inhibitor | 0.201 0.15 DBMET00327 | DBMET00327 | |
| 0.122 | 0.233 | 0.556 | Prostaglandin dehydrogenase inhibitor | 0.556 0.031 DBMET00327 | DBMET00327 | |
| 0.012 | 0.133 | 0.031 | Melatonin 2 agonist | 0.031 0.026 DBMET00327 | DBMET00327 | |
| 0.034 | 0.155 | 0.059 | Heat shock protein 90 beta antagonist | 0.059 0.041 DBMET00327 | DBMET00327 | |
| 0.052 | 0.174 | 0.121 | Alpha 2c adrenoreceptor antagonist | 0.121 0.049 DBMET00327 | DBMET00327 | |
| 0.025 | 0.152 | 0.055 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.055 0.035 DBMET00327 | DBMET00327 | |
| 0.056 | 0.186 | 0.204 | Cyclooxygenase 2 inhibitor | 0.204 0.029 DBMET00327 | DBMET00327 | |
| 0.135 | 0.281 | 0.383 | Alpha-glucosidase inhibitor | 0.383 0.122 DBMET00327 | DBMET00327 | |
| 0.049 | 0.209 | 0.21 | Estrogen receptor beta antagonist | 0.21 0.009 DBMET00327 | DBMET00327 | |
| 0.042 | 0.223 | 0.098 | Uric acid excretion stimulant | 0.098 0.055 DBMET00327 | DBMET00327 | |
| 0.065 | 0.277 | 0.179 | Heat shock protein 90 alpha antagonist | 0.179 0.063 DBMET00327 | DBMET00327 | |
| 0.005 | 0.23 | 0.08 | Leukotriene A4 hydrolase inhibitor | 0.08 0.009 DBMET00327 | DBMET00327 | |
| 0.015 | 0.247 | 0.08 | Elastase inhibitor | 0.08 0.016 DBMET00327 | DBMET00327 | |
| 0.056 | 0.302 | 0.155 | Heat shock protein 90 antagonist | 0.155 0.07 DBMET00327 | DBMET00327 | |
| 0.013 | 0.271 | 0.039 | Estrogen-related receptor beta antagonist | 0.039 0.012 DBMET00327 | DBMET00327 | |
| 0.024 | 0.287 | 0.179 | 5-Lipoxygenase inhibitor | 0.179 0.029 DBMET00327 | DBMET00327 | |
| 0.041 | 0.354 | 0.182 | Estrogen antagonist | 0.182 0.015 DBMET00327 | DBMET00327 | |
| 0.005 | 0.334 | 0.611 | Dopamine D5 antagonist | 0.611 0.003 DBMET00327 | DBMET00327 | |
| 0.052 | 0.41 | 0.168 | Antioxidant | 0.168 0.144 DBMET00327 | DBMET00327 | |
| 0.036 | 0.4 | 0.137 | Dual specificity phosphatase inhibitor | 0.137 0.11 DBMET00327 | DBMET00327 | |
| 0.003 | 0.383 | 0.042 | Estrogen receptor alpha agonist | 0.042 0.02 DBMET00327 | DBMET00327 | |
| 0.003 | 0.413 | 0.096 | Estrogen receptor beta agonist | 0.096 0.012 DBMET00327 | DBMET00327 | |
| 0.004 | 0.492 | 0.022 | Integrin alphaVbeta3 antagonist | 0.022 0.015 DBMET00327 | DBMET00327 | |
| 0.004 | 0.639 | 0.057 | Estrogen agonist | 0.057 0.031 DBMET00327 | DBMET00327 | |
| 0.003 | 0.749 | 0.036 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.036 0.024 DBMET00327 | DBMET00327 | |
| 0.003 | 0.794 | 0.033 | Sphingosine 1-phosphate receptor 3 agonist | 0.033 0.025 DBMET00327 | DBMET00327 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |